J H Barth1, H P Field, A N Mather, S Plein. 1. Clinical Biochemistry, Leeds General Infirmary, Leeds LS1 3EX, UK. julian.barth@leedsth.nhs.uk
Abstract
BACKGROUND: There is growing epidemiological evidence linking serum 25 hydroxy-vitamin D (25(OH)D) concentrations to outcome in cardiovascular and other diseases. We have studied patients with acute myocardial infarction (AMI) to determine if they exhibit an acute phase reaction affecting 25(OH)D. METHODS: Patients (n=32) with first AMI who had been treated with primary percutaneous coronary intervention within 12 h of symptom onset had venous blood samples taken two days, one week, one month and three months after presentation. Samples were analysed for troponin I, C-reactive protein (CRP) and 25(OH)D. RESULTS: All patients had significant rises in troponin confirming the myocardial damage and CRP, both of which resolved by 28 days. In contrast, 25(OH)D remained unchanged throughout the 90-day observation period with a median concentration of 46 nmol/L. CONCLUSION: Serum 25(OH)D does not change after AMI and is likely to be a reliable marker of vitamin D status in patients with cardiovascular disease.
BACKGROUND: There is growing epidemiological evidence linking serum 25 hydroxy-vitamin D (25(OH)D) concentrations to outcome in cardiovascular and other diseases. We have studied patients with acute myocardial infarction (AMI) to determine if they exhibit an acute phase reaction affecting 25(OH)D. METHODS:Patients (n=32) with first AMI who had been treated with primary percutaneous coronary intervention within 12 h of symptom onset had venous blood samples taken two days, one week, one month and three months after presentation. Samples were analysed for troponin I, C-reactive protein (CRP) and 25(OH)D. RESULTS: All patients had significant rises in troponin confirming the myocardial damage and CRP, both of which resolved by 28 days. In contrast, 25(OH)D remained unchanged throughout the 90-day observation period with a median concentration of 46 nmol/L. CONCLUSION: Serum 25(OH)D does not change after AMI and is likely to be a reliable marker of vitamin D status in patients with cardiovascular disease.
Authors: N Binkley; D Coursin; D Krueger; P Iglar; J Heiner; R Illgen; M Squire; J Lappe; P Watson; K Hogan Journal: Osteoporos Int Date: 2016-11-08 Impact factor: 4.507
Authors: Vania B Rezende; Valeria C Sandrim; Ana C Palei; Lorena Machado; Ricardo C Cavalli; Geraldo Duarte; Jose E Tanus-Santos Journal: Mol Biol Rep Date: 2012-10-07 Impact factor: 2.316
Authors: Juraj Smaha; Martin Kužma; Peter Jackuliak; Samuel Nachtmann; Filip Max; Elena Tibenská; Neil Binkley; Juraj Payer Journal: Nutrients Date: 2022-06-07 Impact factor: 6.706
Authors: Kate Madden; Henry A Feldman; Ellen M Smith; Catherine M Gordon; Shannon M Keisling; Ryan M Sullivan; Bruce W Hollis; Anna A Agan; Adrienne G Randolph Journal: Pediatrics Date: 2012-08-06 Impact factor: 7.124
Authors: Tyler Barker; Heidi T May; John R Doty; Donald L Lappe; Kirk U Knowlton; John Carlquist; Kristin Konery; Shannon Inglet; Ben Chisum; Oxana Galenko; Jeffrey L Anderson; Joseph B Muhlestein Journal: Physiol Rep Date: 2021-02
Authors: Helen F Titmarsh; Adam G Gow; Scott Kilpatrick; Jennifer A Cartwright; Elspeth M Milne; Adrian W Philbey; Jacqueline Berry; Ian Handel; Richard J Mellanby Journal: PLoS One Date: 2015-09-02 Impact factor: 3.240